Celltrion’s Omiclov Expands Prescriptions Across Europe

Field-Oriented, Customized Sales Activities
Accelerating Market Expansion

Celltrion is rapidly strengthening its market presence in Europe with "Omeclico" (ingredient: omalizumab), a treatment for chronic idiopathic urticaria and allergic asthma that it introduced as a first mover in the region. The drug is expanding its prescription base and achieving successful bids across Europe.

According to Celltrion on April 13, Omeclico has achieved continued success in bidding processes in Italy, one of the five major EU countries (EU5). To date, a total of 14 regional government-level omalizumab tenders have been held, and Celltrion's Italian subsidiary has won bids in 10 of these regional government tenders. In some areas, such as Umbria, Trentino-Alto Adige, and Toscana, product supply is ramping up, accelerating market penetration. The local subsidiary also achieved meaningful results in the remaining four regional tenders and plans to expand Omeclico supply throughout Italy.

Celltrion's Omeclico, a treatment for chronic idiopathic urticaria and allergic asthma. Celltrion

In the United Kingdom, Celltrion achieved notable results in National Health Service (NHS) tenders. The Celltrion UK subsidiary won all NHS tenders held in four administrative regions, including England, which has the largest omalizumab market. As of January this year, even before the official tenders began, Omeclico had already captured a double-digit market share. With the official supply ramping up, the company expects prescriptions to increase even more rapidly by leveraging its first-mover biosimilar status.

In Germany, Omeclico has also quickly established itself in the market, raising expectations. Celltrion stated that Omeclico, launched in Germany in September last year, achieved a double-digit market share within just one month of sales and continues to grow rapidly. The German subsidiary completed listing contracts with all public health insurers immediately after launch, and has been actively conducting sales and marketing activities targeting healthcare professionals, leveraging its robust existing sales network to drive results.

In Northern Europe, Omeclico's prescription performance is also becoming evident. In Denmark, where Celltrion won the national tender, the company coordinated closely with the tendering agency to launch Omeclico four months ahead of schedule, and secured exclusive supply status until September this year. As a result, Omeclico held a market share of 98% (according to IQVIA and market data) in Denmark as of January, effectively dominating the market. In Finland, Omeclico achieved a 73% market share as of February, demonstrating a rapid shift from original products to Omeclico across key Northern European countries.

Aerial view of Celltrion Plant 2 in Songdo, Incheon. / Incheon - Photo by Hyunmin Kim

Omeclico is also seeing continued expansion in prescriptions in Spain and the Netherlands. In Spain, Celltrion was selected as the top supplier in public procurement tenders for all public healthcare institutions in the major regions of Catalunya and the Basque Country. The Celltrion Spain subsidiary, in addition to winning regional and local public tenders, has expanded supply to individual hospitals, achieving an 80% market share in the local omalizumab market. In the Netherlands, home to the European Medicines Agency (EMA), Celltrion won tenders for multiple hospital groups and has achieved a market share exceeding 70%. Notably, the cost-saving effects of biosimilars have positively influenced the market, leading to rapid tendering and supply immediately after Omeclico's launch.

Celltrion has identified product competitiveness, stable supply, and field-oriented marketing activities as the main drivers supporting Omeclico’s growth in the European market. The company also plans to sequentially launch the Omeclico 300mg formulation, tailored to local healthcare providers’ and patients’ needs, in major European countries in line with agreements with the original manufacturer. This is expected to further accelerate the growth in prescriptions by enhancing product competitiveness.

Ha Taehoon, Head of Celltrion Europe, stated, “From the initial launch, Omeclico has continued to win bids and expand prescriptions across European countries, demonstrating the tangible results of Celltrion’s field-oriented sales and marketing activities in the European market. We plan to continuously expand our sales regions so that our achievements in each country can be extended throughout Europe, and we will do our utmost to establish Omeclico as a new revenue driver supporting Celltrion’s overall performance growth.”

This content was produced with the assistance of AI translation services.